IFM Investors Pty Ltd Grows Position in Edwards Lifesciences Corporation (NYSE:EW)

IFM Investors Pty Ltd grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 132,549 shares of the medical research company's stock after acquiring an additional 11,220 shares during the period. IFM Investors Pty Ltd's holdings in Edwards Lifesciences were worth $8,747,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Prosperity Consulting Group LLC lifted its stake in Edwards Lifesciences by 3.6% in the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock valued at $289,000 after buying an additional 134 shares during the period. Arlington Trust Co LLC lifted its position in shares of Edwards Lifesciences by 1.2% during the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after acquiring an additional 135 shares during the period. Versant Capital Management Inc boosted its stake in Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after acquiring an additional 145 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares during the period. Finally, Kera Capital Partners Inc. increased its stake in Edwards Lifesciences by 5.0% in the first quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock valued at $224,000 after purchasing an additional 148 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the transaction, the vice president owned 33,496 shares of the company's stock, valued at $2,514,879.68. The trade was a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,348 shares of company stock valued at $2,977,683 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the topic of a number of research analyst reports. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a report on Friday, April 25th. Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Finally, Evercore ISI upped their price objective on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the stock an "in-line" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $80.40.

Edwards Lifesciences Stock Down 0.3%

Shares of Edwards Lifesciences stock traded down $0.25 on Tuesday, reaching $76.44. The company's stock had a trading volume of 2,411,988 shares, compared to its average volume of 5,244,792. The company has a market capitalization of $44.84 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 3.85 and a beta of 1.11. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The firm's fifty day simple moving average is $76.14 and its two-hundred day simple moving average is $73.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the previous year, the firm posted $0.66 EPS. The firm's revenue was up 6.2% on a year-over-year basis. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.